Research Progress of 1-Deamino-8-D-Arginine-Vasopressin in the Treatment of Patients With Hemophilia

Abstract

1-deamino-8-D-arginine-vasopressin (DDAVP) is a synthetic compound of the antidiuretic hormone vasopressin, which can increase plasma concentration of factor Ⅷ (FⅧ), von Willebrand factor (vWF), and tissue plasminogen activator (t-PA) in normal subjects and patients with hemophilia A(HA). It has been using for the treatment or prevention of bleeding episodes caused by mild HA and type 1 von Willebrand disease (vWD) over the past 30 years on aboard. More and more studies have demonstrated the clinical efficacy of DDAVP for carriers of female HA, patients of HA with inhibitors and acquired HA, even for patients with haemophilia B(HB). DDAVP is safe, cheap and carries no risk of transmitting of blood-borne viral infections particularly during the human immunodeficiency virus (HIV) and hepatitis virus, and developing inhibitor antibodies upon repeated treatments with FⅧ concentrates. Thus, in every patient with newly diagnosed as hemophilia, a test infusion/injection of DDAVP should be carried out to assess the future usefulness of the compound. Key words: hemophilia; 1-deamino-8-D-arginine-vasopressin; drug therapy